Welcome to our dedicated page for Solesence news (Ticker: SLSN), a resource for investors and traders seeking the latest updates and insights on Solesence stock.
Solésence, Inc. (Nasdaq: SLSN) is a scientifically driven health care solutions company in the household and personal products space, focused on beauty and life science categories. Company news frequently centers on its mineral-based skin care, sun care and color cosmetics activities, which it positions around skin health, aesthetics and daily wearability.
Investors following SLSN news can expect regular updates on financial performance, including quarterly earnings results, revenue trends and gross margin commentary, as reflected in the company’s first, second and third quarter 2025 press releases. These announcements often discuss shipment and production volumes, non-GAAP measures such as adjusted EBITDA, and the impact of operational changes on profitability.
Solésence also issues news about corporate developments, such as its rebranding from Nanophase Technologies to Solésence, its uplisting to Nasdaq under the SLSN ticker, and its inclusion in the Russell 3000 and Russell 2000 indexes. Leadership changes are another recurring theme, including the promotion of Kevin Cureton to President and Chief Executive Officer, the appointment of Laura Riffner as Chief Financial Officer, and the creation of a Vice President of Innovation and Product Integrity role.
Operational and strategic updates appear in releases about manufacturing consolidation, increased automation, expanded debt facilities, and the unification of research and development, product development, regulatory and quality functions. For those tracking the intersection of beauty and skin health, Solésence news also highlights intellectual property milestones and recognition within the beauty industry. This page aggregates such company-issued information so readers can monitor how Solésence describes its progress and strategic direction over time.
Solésence (Nasdaq: SLSN) reported second quarter 2026 revenue of $15.3 million, down from $20.4 million a year earlier, when results benefited from a one-time product launch and inventory pipeline fill. Gross profit was $4.7 million with a 31% gross margin, compared to $6.4 million and 32% in Q2 2025.
The company recorded a net loss of $158,000 versus net income of $3.2 million in the prior-year quarter. For the first six months of 2026, net revenue was $28.3 million and the net loss was $1.1 million. Adjusted EBITDA for Q2 2026 was $523,000, down from $3.7 million.
As of June 30, 2026, Solésence reported $1.0 million in cash, total assets of $46.4 million, current liabilities of $26.0 million, and stockholders’ equity of $13.2 million. The company completed its review of historical inventory costing allocation methodologies and filed its Form 10-Q. Management will discuss results on a conference call at 5:00 p.m. ET on August 19, 2026.
Solésence (Nasdaq: SLSN) has rescheduled its second quarter 2026 conference call and webcast to Wednesday, August 19, 2026, at 5:00 p.m. ET (4:00 p.m. CT). The company said the additional time will allow completion of its quarterly financial reporting and review process.
Investors can access the event via webcast, a registered dial-in with personalized PIN, or through Solésence’s investor relations website.
Solésence (Nasdaq: SLSN) will report its second quarter 2026 financial results before the market opens on Tuesday, August 11, 2026, and will host a conference call and webcast the same day at 7:30 a.m. CT / 8:30 a.m. ET, featuring its CEO and CFO.
Solésence (Nasdaq: SLSN) launched two patent-backed, market-ready scalp care products for brand partners worldwide: Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen, expanding its presence in the hair and scalp segment. The products leverage Solésence’s proprietary WHSPR™ and Kleair™ technology platforms as part of its Transform and Transcend initiative.
Revitalizing Scalp Serum, formulated with WHSPR™ and 5% niacinamide, delivers clinically proven improvements in barrier recovery, erythema mitigation, moisture, and sebum control, supporting OTC skin health claims. Scalp Screen Dry Shampoo SPF 45+ Sunscreen, built on Kleair™, combines broad-spectrum mineral UV protection blocking over 97% of UV radiation with oil-absorbing and scalp-soothing benefits, and has been named a 2026 Cosmopack Award finalist for formulation.
Solésence (Nasdaq:SLSN) was named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards, presented by HPCi Media. The award recognizes client satisfaction, innovation, product development, reliability, scalability, service, and speed-to-market.
Solésence has earned 12 industry awards since 2022 and is launching new skin health and healing technologies, aiming to extend its ingredient-led, patent-backed platform beyond environmental protection into active skin restoration across beauty, health, and wellness.
Solésence (Nasdaq:SLSN) announced its prototype Day Mode Hero Concealer SPF 50+ won three categories at the 2026 Cosmetics & Toiletries Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin.
This marks Solésence’s fourth consecutive year of Allē recognition, highlighting its proprietary Kleair™, WHSPR™, and Chromalüm™ technologies.
Solésence (Nasdaq:SLSN) announced support for a landmark UK report, “A Preventable Crisis: The Case for a National UV Safety Strategy.” The report, led by the UK APPG for Beauty, Hair & Wellbeing and backed by the UV Safety Coalition, calls for a national UV safety strategy.
Recommendations focus on year-round UV protection, public education, better access to protection products, and treating UV protection as an essential good. Solésence participates in the UV Safety Coalition and plans to help implement non-governmental recommendations and promote daily UV protection behaviors in the UK.
Solésence (Nasdaq:SLSN) reported Q1 2026 revenue of $13.0 million, down from $14.6 million in 2025, with gross profit of $3.3 million. Gross margin improved to 26% from 23%. The company posted a net loss of about $0.8 million versus prior net income of $0.08 million.
According to Solésence, Q1 reflected execution of its Transform and Transcend initiative, emphasizing operational excellence, expanded OTC claims via WHSPR™ and Chromalüm™ technologies, and board strengthening with new independent director Marc James.
Solésence (Nasdaq:SLSN) launched two proprietary skin health platforms, WHSPR™ and Chromalüm™, now commercially available through finished goods for brand partners worldwide. The technologies expand Solésence's ingredient portfolio and support OTC-grade sensitive skin and environmental protection claims across skincare, suncare, and color cosmetics.
WHSPR™ is an advanced allantoin delivery system that enables high-concentration, stable use in anhydrous formats and supports OTC skin and lip protectant claims. Clinical studies showed statistically significant improvements, including up to 63% redness reduction and 112% immediate hydration. Chromalüm™ integrates precision color with Kleair™ to provide broad-spectrum SPF and targeted HEV protection for high-sheer and full-coverage color cosmetics.
Solésence (Nasdaq: SLSN) will report first quarter 2026 financial results on Tuesday, May 12, 2026 after the market opens and will host a live conference call and webcast the same day.
Call: 7:30 a.m. CT / 8:30 a.m. ET. Speakers: Kevin Cureton, President & CEO, and Laura Riffner, CFO. Webcast and registration links available on the investor relations site.